20BB-zT2

N/A

Report date: 2024/03/11 13:54:43

Base Information

Drug Name20BB-zT2

Drug Alias Name20BB-zT220BBzT2

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsUpdating

Therapy Area/IndicationsLymphomaLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNew Zealand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesWellington Zhaotai Therapies Limited (Wztl)

China Registration ClassN/A

Develop Information

Active CompaniesWellington Zhaotai Therapies Limited (Wztl)

Inactive CompaniesN/A

Active IndicationsLymphomaLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A